Targeting high circDNA2v levels in colorectal cancer induces cellular senescence and elicits an anti-tumor secretome

  • Cell Rep. 2024 Apr 23;43(4):114111. doi: 10.1016/j.celrep.2024.114111.
Shuang Wu  1 Xiangyu Dai  1 Yang Xia  1 Qingsong Zhao  1 Heng Zhao  1 Zhimin Shi  1 Xin Yin  1 Xue Liu  1 Aijie Zhang  1 Zhihui Yao  2 Hao Zhang  3 Qun Li  1 Rick Francis Thorne  2 Shangxin Zhang  3 Weiwei Sheng  4 Wanglai Hu  5 Hao Gu  6
Affiliations
  • 1. Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, China.
  • 2. Translational Research Institute, People's Hospital of Zhengzhou University, Academy of Medical Science, Henan International Joint Laboratory of Non-coding RNA and Metabolism in Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou 450003, China.
  • 3. Department of Gastrointestinal Surgery, Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
  • 4. Department of Gastrointestinal Surgery, Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. Electronic address: [email protected].
  • 5. Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, China; Translational Research Institute, People's Hospital of Zhengzhou University, Academy of Medical Science, Henan International Joint Laboratory of Non-coding RNA and Metabolism in Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou 450003, China. Electronic address: [email protected].
  • 6. Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, China. Electronic address: [email protected].
Abstract

The efficacy of immunotherapy against colorectal Cancer (CRC) is impaired by insufficient immune cell recruitment into the tumor microenvironment. Our study shows that targeting circDNA2v, a circular RNA commonly overexpressed in CRC, can be exploited to elicit cytotoxic T cell recruitment. circDNA2v functions through binding to IGF2BP3, preventing its ubiquitination, and prolonging the IGF2BP3 half-life, which in turn sustains mRNA levels of the protooncogene c-Myc. Targeting circDNA2v by gene silencing downregulates c-Myc to concordantly induce tumor cell senescence and the release of proinflammatory mediators. Production of CXCL10 and interleukin-9 by CRC cells is elicited through JAK-STAT1 signaling, in turn promoting the chemotactic and cytolytic activities of CD8+ T cells. Clinical evidence associates increased circDNA2v expression in CRC tissues with reductions in CD8+ T cell infiltration and worse outcomes. The regulatory relationship between circDNA2v, cellular senescence, and tumor-infiltrating lymphocytes thus provides a rational approach for improving immunotherapy in CRC.

Keywords
CP: Cancer.
Products